Organ on a Chip

#

Organ-on-a-chip and microphysiological systems replicate the dynamic, multi-cellular environments of human organs in microfluidic devices, enabling high-fidelity studies of drug effects, disease mechanisms, and toxicity. By mimicking tissue-tissue interfaces, fluid flow, and mechanical forces, these platforms offer human-relevant alternatives to traditional animal models, driving advances in personalized medicine and regulatory-approved drug development tools.

Emulate Liver-on-a-Chip Identifies Hepatotoxicity

#

The Emulate liver-on-a-chip model correctly identified hepatotoxicity in 87% of drugs (see “performance assessment” link below) that had tested as safe in animal models but were later found toxic in humans. The platform recapitulated human-specific metabolic dynamics, including albumin secretion and mechanical stimuli in the extracellular matrix, validating its biological accuracy. This success highlighted the superiority of human-relevant microphysiological systems over animal models for predicting drug-induced liver injury.
Tumor organoids for cancer research and personalized medicine
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
What are NAMs?

Acetaminophen Toxicity Mechanism

#

Liver-on-a-chip technology equipped with nanotechnology-based optoelectronic sensors identified that acetaminophen blocks cellular respiration in minutes at much lower doses than previously believed. Sensors placed inside the bionic tissue detected rapid changes in oxygen uptake, revealing an ultra-rapid mitochondrial respiration impairment component not captured in legacy in vivo studies. This discovery provides a human-specific explanation for rare off-target effects and skin reactions, transforming safety protocols for one of the world’s most common medications.
Hepatotoxic assessment in a microphysiological system What are NAMs?

Lung-on-a-Chip for Antiviral Efficacy

#

A human lung-on-a-chip system was used to test RNA-based antiviral therapies for influenza, showing significant reduction in viral replication and inflammatory responses with minimal off-target toxicity. The platform demonstrated efficacy and safety under physiologically relevant conditions such as air-liquid interface and dynamic flow. This provided a human-relevant platform for antiviral drug testing, successfully overcoming the limitations of static cultures and animal models.
Lung-On-A-Chip Technologies for Disease Modeling and Drug Development
Human Lung-on-a-Chip Model Demonstrates Potential for Testing Preclinical Influenza Therapeutics
Revolutionizing respiratory health research

Lung-on-a-Chip for Tumor Heterogeneity & Drug Resistance

#

Microfluidic lung-on-a-chip platforms modeled lung cancer microenvironments, enabling label-free real-time classification of tumor cells and the tracking of drug-resistant subpopulations like EGFR mutations. The technology demonstrated the ability to observe tumor heterogeneity and resistance dynamics in a human-relevant system, validating its predictive power. These insights have accelerated the development of targeted therapies and personalized treatment strategies for lung cancer.
Progress and application of lung-on-a-chip for lung cancer
The potential of lung-on-a-chip as an alternative to animal testing
Microfluidic lung cancer models: Bridging clinical treatment strategies and tumor microenvironment recapitulation

Liver and Skin Organ-on-a-Chip for PK-PD Studies

#

The HUMIMIC Chip2 integrated liver spheroids and skin models to study pharmacokinetic-pharmacodynamic (PK-PD) relationships under chemical exposure. The platform’s utility for quantifying drug metabolism and toxicity was validated in a human-relevant, multi-organ context. This advancement directly supported regulatory acceptance of organ-on-a-chip technologies as essential drug development tools.
Organ-on-a-chip meets artificial intelligence in drug evaluation
Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation

ALS Pathogenesis and Early Biomarkers

#

Human spinal cord organ-chips integrated with vascular interfaces modeled early sporadic Amyotrophic Lateral Sclerosis (ALS), uncovering neurofilament dysregulation and synaptic signaling defects. Multi-omics analysis confirmed these molecular changes occur before overt neuron loss, mirroring clinical biomarkers that are difficult to detect in animal models. This technology offers a human-relevant platform to study early disease progression and identify therapeutic targets before irreversible nerve damage occurs.
Organ-Chip ALS Model Uses Patient iPSCs to Uncover Early Disease Progression
An organ-chip model of sporadic ALS using iPSC

GABAergic Signaling in Cancer Invasion

#

Patient-derived tumor organ-chips proved that tumor-derived GABA acts as a marker of poor prognosis and directly promotes invasion in metastatic colorectal cancer. Interrogating the underlying biology on-chip demonstrated that inhibiting GABA synthesis significantly reduced invasive behavior, capturing patient-specific heterogeneity more faithfully than static cultures. This work establishes a new therapeutic target for colorectal cancer and validates the ability of organ-chips to replicate the complex tumor microenvironment.
GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer

Cervical Protective Role in Dysbiosis

#

Linked Cervix and Vagina Organ-Chips demonstrated that cervical mucus actively modulates vaginal inflammation and protects the epithelium from injury during dysbiosis. Exposure to cervix-derived mucus on-chip reduced inflammatory responses and altered protein expression profiles, identifying potential new biomarkers for bacterial vaginosis. This discovery uncovers human-specific protective mechanisms that cannot be studied in animal models, facilitating the discovery of new feminine health therapeutics.
Cervical mucus in linked human Cervix and Vagina Chips modulates vaginal dysbiosis

Lung-on-a-Chip Replicates Human Lung Disease and Drug Responses

#

Microfluidic chips lined with human lung cells modeled pulmonary edema, COPD, and drug toxicity with high fidelity. This model demonstrated superior predictive value over animal models for lung disease and toxicity and is now recognized by the FDA as a valid testing platform for specific drug submissions. The impact of this technology is the enablement of more accurate modeling of human lung responses to drugs and diseases.
Reconstituting Organ-Level Lung Functions on a Chip
A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice

Human Skin-Lymphoreticular Model-on-Chip for Inflammatory Skin Diseases

#

Researchers developed a human-based skin-lymphoreticular model-on-chip emulating inflammatory skin conditions by capturing immune-skin interactions on a microfluidic platform. The utility for studying atopic dermatitis and related diseases was validated through the observation of complex cellular interactions. This advancement effectively eliminates the need for animal models in studying inflammatory skin diseases.
A Human-Based Skin-Lymphoreticular Model-on-Chip to Emulate Inflammatory Skin Conditions